How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines

Advances in Therapy

Volumn 25, Issue 7, 2008, Pages 681-702

  Ansari, Ghazal ^a   Mojtahedzadeh, Mojtaba ^a   Kajbaf, Farshad ^a   Najafi, Atabak ^b   Khajavi, Mohammad Reza ^b   Khalili, Hossein ^a   Rouini, Mohammad Reza ^a   Ahmadi, Hadi ^b   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Critically ill patients; Glucose; Insulin; Metformin; Stress induced hyperglycaemia

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; CYTOKINE; INSULIN; METFORMIN; NITRIC OXIDE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CLINICAL PROTOCOLS; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTENSIVE CARE UNITS; METFORMIN; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; YOUNG ADULT;

EID: 58149330641     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0075-1     Document Type: Article

References (64)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic infammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:1117-1123.
2. Hadidi E, Mojtahedzadeh M, Paknejad MH, et al. Alterations of blood IL-8, TGF-β1 and nitric oxide levels in relation to blood cells in patients with acute brain injury. Terapy. 2006;3:413-419.
3. Salari P, Mojtahedzadeh M, Najaf A, et al. Comparison of the Effect of aminophylline and low PEEP vs. high PEEP on EGF concentration in critically ill patients with ALI/ARDS. J Clin Pharm Ter. 2005;30:139-144. (Pubitemid 41583608)
4. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. 2007;18:240-245. (Pubitemid 46743045)
5. Kajbaf F, Mojtahedzadeh M, Abdollahi M. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Terapy. 2007;4:97-106. (Pubitemid 46322256)
6. Umpierrez GE, Isaacs SD, Bazargan N, You X, Taler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982. (Pubitemid 36121050)
7. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycemia. Best Pract Res Clin Endocrinol Metab. 2001;15:533-551.
8. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-1367.
9. Mesotten D, Delhanty PJ, Vanderhoydonc F, et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab. 2002;87:5516-5523. (Pubitemid 36034354)
10. Gennari FJ. Hypokalemia. N Engl J Med. 1998;339:451-458. (Pubitemid 28377688)
11. Delva P, Degan M, Trettene M, Lechi A. Insulin and glucose mediate opposite intracellular ionized magnesium variations in human lymphocytes. J Endocrinol. 2006;190:711-718. (Pubitemid 44560246)
12. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365-373. (Pubitemid 41219650)
13. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579. (Pubitemid 126537875)
14. Pavlovic D, Kocic R, Kocic G, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab. 2000;2:251-256. (Pubitemid 33072194)
15. Tessier D, Maheux P, Khalil A, Fülöp T. Effects of gliclazide versus metformin on the clinical profle and lipid peroxidation markers in type 2 diabetes. Metabolism. 1999;48:897-903. (Pubitemid 29310047)
16. Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinfammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Tromb Vasc Biol. 2006;26:611-617.
17. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classifcation system. Crit Care Med. 1985;13:818-829. (Pubitemid 15250137)
18. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-710.
19. Miranda DR, de Rijk A, Schaufeli W. Simplifed Terapeutic Intervention Scoring System: the TISS-28 items-results from a multicenter study. Crit Care Med. 1996;24:64-73.
20. Astaneie F, Afshari M, Mojtahedi A, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res. 2005;36:376-381. (Pubitemid 40798392)
21. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461. (Pubitemid 43200296)
22. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79:992-1000. (Pubitemid 39007018)
23. Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. Endocr Tract. 2004;10(suppl 2):46-52.
24. Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA. Infuence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc. 2005;80:1558-1567. (Pubitemid 41747057)
25. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome beneft of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31:359-366. (Pubitemid 36232926)
26. Soltan-Sharif MS, Mojtahedzadeh M, Najaf A, et al. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol. 2007;26:697-703. (Pubitemid 350157338)
27. Larijani B, Afshari M, Astanehi-Asghari F, et al. Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes. Terapy. 2006;3:119-123.
28. Vazin A, Mojtahedzadeh M, Najaf A, Khalilzadeh A, Abdollahi M. Relationship between duration, fatality rate and severity of disease and serum epidermal growth factor in human acute lung injury. Terapy. 2005;2:255-259. (Pubitemid 40450569)
29. Salari P, Mojtahedzadeh M, Abdollahi M. Infuence of serum epidermal growth factor on mechanical ventilation and survival in patients with acute respiratory distress syndrome. Terapy. 2005;2:393-398. (Pubitemid 40790198)
30. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother. 2005;59:302-306. (Pubitemid 41058720)
31. Chang HR, Bistrian B. The role of cytokines in the catabolic consequences of infection and injury. JPEN J Parenter Enteral Nutr. 1998;22:156-166. (Pubitemid 28194473)
32. Orshal JM, Khalil RA. Interleukin-6 impairs endothelium-dependent NO-cGMP-mediated relaxation and enhances contraction in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol. 2004;286:R1013-R1023. (Pubitemid 38661388)
33. Warne JP. Tumour necrosis factor α: a key regulator of adipose tissue mass. J Endocrinol. 2003;177:351-355. (Pubitemid 36722289)
34. Hotamisligil GS. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245:621-625. (Pubitemid 29278870)
35. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-infammatory Effect? J Clin Endocrinol Metab. 2001;86:3257-3265. (Pubitemid 32674120)
36. Andersson CX, Sopasakis VR, Wallerstedt E, Smith U. Insulin antagonizes interleukin-6 signaling and is anti-infammatory in 3T3-L1 adipocytes. J Biol Chem. 2007;282:9430-9435. (Pubitemid 47104618)
37. Hansen TK, Tiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts anti-infammatory Effects in critically ill patients and counteracts the adverse Effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88:1082-1088. (Pubitemid 36337759)
38. Carlsen SM, Waage A, Grill V, Følling I. Metformin increases circulating tumor necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease. Cytokine. 1998;10:66-69. (Pubitemid 28068594)
39. Biarnés J, Fernández-Real JM, Fernández- Castañer M, del Mar García M, Soler J, Ricart W. Diferential regulation of insulin action and tumor necrosis factor alpha system activity by metformin. Metabolism. 2005;54:235-239. (Pubitemid 40174853)
40. Mavrommatis AC, Teodoridis T, Economou M, et al. Activation of the fbrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med. 2001;27:1853-1859. (Pubitemid 33145069)
41. Hadigan C, Meigs JB, Rabe J, et al. Framingham Heart Study. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2001;86:939-943. (Pubitemid 32207521)
42. Grant PJ. The Effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64-66.
43. Charles MA, Morange P, Eschwège E, André P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fbrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 1998;21:1967-1972. (Pubitemid 28478302)
44. Bergheim I, Luyendyk J P, Steele C, et al. Metformin prevents endotoxin-induced liver injury afer partial hepatectomy. J Pharmacol Exp Ter. 2006;316:1053-1061. (Pubitemid 43345278)
45. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the pro-infammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab. 2002;87:1419-1422. (Pubitemid 36121118)
46. Healy AM, Gelehrter TD. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1994;269:19095-19100. (Pubitemid 24226231)
47. Fearns C, Loskutof DJ. Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol. 1997;150:579-590. (Pubitemid 27073786)
48. Vaughan DE. PAI-1 and atherothrombosis. J Tromb Haemost. 2005;3:1879-1883. (Pubitemid 41716575)
49. Krebs M, Geiger M, Polak K, et al. Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule afer triacylglycerol infusion in man. Tromb Haemost. 2003;90:422-428. (Pubitemid 37138766)
50. Billiar TR. Nitric oxide: novel biology with clinical relevance. Ann Surg. 1995;221:339-349.
51. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcrof JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002;105:213-217. (Pubitemid 34084321)
52. Dengim AC, Morrow SE, Ku J, Zar HA, Nakayama DK. Nitric oxide inhibits peroxide-mediated endothelial toxicity. J Surg Res. 1998;75:127-134. (Pubitemid 28304317)
53. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab. 2000;85:2572-2575. (Pubitemid 32269217)
54. Worthley MI, Holmes AS, Willoughby SR, et al. The deleterious Effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol. 2007;49:304-310. (Pubitemid 46097375)
55. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest. 2005;115:2277-2286. (Pubitemid 41134169)
56. Vazin A, Mojtahedzadeh M, Salehifar E, et al. Future drugs for treatment of acute respiratory distress syndrome. Int J Pharmacol. 2005;1:9-16.
57. Ewis SA, Abdel-Rahman MS. Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats. J Appl Toxicol. 1995;15:387-390.
58. Bonnefont-Rousselot D, Raji B, Walrand S, et al. An intracellular modulation of free radical production could contribute to the benefcial Effects of metformin towards oxidative stress. Metabolism. 2003;52:586-589. (Pubitemid 36896285)
59. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51:2074-2081. (Pubitemid 34729010)
60. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125-139.
61. Setter SM, Iltz JL, Tams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ter. 2003;25:2991-3026. (Pubitemid 38096142)
62. Lalau JD, Race JM. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab. 2000;2:131-137.
63. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;(1):CD002967.
64. Mojtahedzadeh M, Rouini MR, Kajbaf F, et al. Advantage of adjunct metformin and insulin therapy in the management of glycemia in critically ill patients. Evidence for nonoccurrence of lactic acidosis and needing to parenteral metformin. Arch Med Sci. 2008;4:174-181.